Chemotherapy-Induced Diarrhea (CID) (Toxicology) - Drugs in Development, 2021
Summary Chemotherapy-Induced Diarrhea (CID) (Toxicology) - Drugs in Development, 2021 provides an overview of the Chemotherapy-Induced Diarrhea (CID) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Chemotherapy-Induced Diarrhea (CID), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy-Induced Diarrhea (CID) and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: * This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase. * Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the Global Therapeutic Landscape of Chemotherapy-Induced Diarrhea (CID) (Toxicology). - The report reviews pipeline therapeutics for Chemotherapy-Induced Diarrhea (CID) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The report covers pipeline products based on various stages of development ranging from discovery till pre-registration. - The report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive MoA, R&D Brief, Licensing and Collaboration details & Other Developmental Activities. - The report reviews key players involved in the development of Chemotherapy-Induced Diarrhea (CID) (Toxicology) therapeutics and enlists all their major and minor projects. - The report assesses Chemotherapy-Induced Diarrhea (CID) (Toxicology) therapeutics based on Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. - The report summarizes all the dormant and discontinued pipeline projects. - The report reviews latest news related to pipeline therapeutics for Chemotherapy-Induced Diarrhea (CID) (Toxicology).
Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective Research and Development (R&D) strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Identify and understand important and diverse types of therapeutics under development for Chemotherapy-Induced Diarrhea (CID) (Toxicology). - Identify potential new clients or partners in the target demographic. - Develop strategic initiatives by understanding the focus areas of leading companies. - Plan Mergers and Acquisitions (M&A) effectively by identifying key players and it’s most promising pipeline therapeutics. - Devise corrective measures for pipeline projects by understanding Chemotherapy-Induced Diarrhea (CID) (Toxicology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Our reports have been used by over 10K customers, including:
Intravenous (IV) solutions are a complete mix of essential nutrients which are intended to replenish fluid losses, treat electrolyte imbalances and maintain fluid balance in intravenous therapy. They also provide required nutrients to the patients suffering from diabetes, cancer and other diseases. Intravenous solutions...
Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease - Drugs in Development, 2021, provides an overview of the Non Alcoholic Fatty Liver Disease (Gastrointestinal)...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
646 pages •
By Global Industry Analysts
• May 2021
Global Laparoscopic Devices Market to Reach $15.8 Billion by 2026
Laparoscopy is a form of minimally invasive surgery used in studying organs in pelvic and abdominal area of the body. The introduction of laparoscopic techniques revolutionized the surgical world through a gradual...
120 pages •
By Infiniti Research Limited
• Mar 2021
Global Pathology Instruments Market 2021-2025 The analyst has been monitoring the pathology instruments market and it is poised to grow by $ 1.23 bn during 2021-2025 progressing at a CAGR of 6% during the forecast period. Our report on pathology instruments market provides a holistic analysis, market size and forecast,...
Melanoma - Epidemiology Forecast to 2029
Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of the skin (World Health Organization, 2017).Melanocytes are embryological derivatives of neural crest tissue, and...
278 pages •
By Global Industry Analysts
• Apr 2021
- Global Anatomic Pathology Market to Reach $26.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Anatomic Pathology estimated at US$18.7 Billion in the year 2020, is projected to reach a revised size of US$26.3 Billion by 2027, growing at a CAGR of 4.9% over the analysis period 2020-2027....
185 pages •
By Global Industry Analysts
• Apr 2021
- Global Pathology Instruments Market to Reach $4.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Pathology Instruments estimated at US$3 Billion in the year 2020, is projected to reach a revised size of US$4.3 Billion by 2027, growing at a CAGR of 5.2% over the analysis period 2020-2027....
The Global Magnetic Beads Market size is expected to reach $2 billion by 2026, rising at a market growth of 12.7% CAGR during the forecast period. Magnetic beads refer to a tool, which is made up of small particles of iron oxides like magnetite that provide superparamagnetic properties to these beads. They do not attract one another when they...
200 pages •
By The Business Research Company
• Mar 2021
Major players in the ultra-low temperature freezers market are Arctiko, Eppendorf, Esco Micro Pte Ltd, Haier, Helmer Scientific, Bionics Scientific Technologies (P). Ltd, PHC Holdings Corporation, Labcold Ltd, Remi Group, and Stirling Ultracold. The global ultra-low temperature freezers market is expected to decline from $633.94 million...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.